Dr. Pierre Massion, chair of LUNGevity’s Scientific Advisory Board, is a world-renowned and highly-published expert in the early detection of lung cancer. Because there currently is no wide-spread, cost-effective diagnostic for lung cancer, he has spent years immersed in the details of lung cancer in order to devise a method of finding early stage lung cancer before it becomes fatal.
Dr. Massion is best known for his work on proteomic biomarkers of lung cancer, where he analyzes the body’s proteins to determine if there are deviations which could indicate the beginnings of disease. If lung cancer is found its earliest phases, it can be highly treatable. Therefore determining if a patient has lung cancer before they have symptoms is an essential part of improving survivorship of this disease. “I see people who are exposed to risk factors for lung cancer,” he explains, “and we are trying to see if they have it or not.”